Incyte 2014 Annual Report
to Stockholders
Jakafi® (ruxolitinib)
Prescribing Information

is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs, primarily for oncology.

Incyte Reports 2015 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Incyte’s Emerging Development Pipeline Described in Eleven Abstracts at 2015 AACR Annual Meeting
Incyte to Establish European Headquarters in Geneva, Switzerland
Jakafi® (ruxolitinib)
Connecting to Access, Reimbursement, Education and Support
To learn more, click here